CHINARES PHARMA's asthma inhalation powder has been approved by the FDA for market launch
China Resources Pharmaceutical (03320.HK) announced that its subsidiary Runsheng Pharmaceutical has received approval from the U.S. Food and Drug Administration (FDA) for the market launch of salmeterol/fluticasone inhalation powder, marking the first time the FDA has approved an inhalation powder developed independently by a Chinese pharmaceutical company.
The salmeterol/fluticasone inhalation powder is used in a combination therapy (bronchodilator and inhaled corticosteroid) for the regular treatment of reversible obstructive airway diseases, including asthma in adults and children
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments